Quick orientationEvidence update: 6 October 2026
What is SS-31 / Elamipretide?
SS-31, or elamipretide, is a mitochondria-targeting tetrapeptide. It is designed to accumulate around the inner mitochondrial membrane and interact with cardiolipin - a lipid that helps the cell's energy machinery stay organised.
Why people are interested
The potential benefits, unpacked.
Here are the goals and claims that bring readers to this guide. The evidence note shows which part is demonstrated, early research or still a question.
The headline interest
Human trials span mitochondrial disease and other conditions; regulatory status/indications are specific and evolving.
What the mechanism suggests
Mitochondria-targeting tetrapeptide that associates with cardiolipin and is studied for mitochondrial membrane/bioenergetic function.
What still needs proving
The key question is whether the claimed benefit has been demonstrated in controlled human studies using the same compound, route and population.
What is it actually doing?
Mitochondria-targeting tetrapeptide that associates with cardiolipin and is studied for mitochondrial membrane/bioenergetic function.
The important distinction is between changing a biomarker or pathway and producing a meaningful outcome that people can feel, measure or sustain.
Results at a glanceHuman evidence
What did the studies actually find?
Human study deep dive
The most informative human evidence we could identify is translated below, with the original source linked.
Study evidenceStudy deep dives
The important studies, translated into normal English.
Each synopsis keeps the trial design, actual results and limitations together. Graphs below are redrawn from the cited numerical results so you can see the size of the effect without having to decode a journal figure.
Barth syndrome trial and FDA accelerated approval
12-patient crossover trial plus long open-label extension; FDA accelerated approval in 2025The blinded 12-week crossover portion did not meet its two primary endpoints. Longer open-label data showed improvements including 6-minute walk distance, and FDA later granted accelerated approval based on improved knee-extensor muscle strength for Barth syndrome patients weighing at least 30 kg.
SS-31/elamipretide now has a real US medicine story—but for a rare mitochondrial disease, not generic energy or anti-ageing.
What it doesn't prove: Accelerated approval relies on an intermediate clinical endpoint and requires confirmatory evidence.
Read the original study / source ↗
Dosing referenceResearch, licensed & reported protocols
What doses and schedules are actually documented?
Human research or licensed product information is separated from clinic and community practice. These are source-attributed reference protocols, not personalised dosing recommendations.
Human research / licensed or product dosing
| Protocol / context | Amount & frequency | Duration | Titration | Evidence |
|---|---|---|---|---|
| Forzinity — FDA-approved | 40 mg SC once daily | Long-term for indicated patients | Fixed | FDA accelerated approval; Barth syndrome ≥30 kg |
| SPIBA-201 randomized phase | 40 mg SC once daily | 28-week crossover study; 12-week treatment periods in FDA review | Fixed | Human pivotal/supportive trial |
| Open-label extension | 40 mg SC once daily | Up to 192 weeks; participants followed through long extension | Fixed | Human long-term study |
Community / clinic / specialist protocols
| Pattern | Amount & frequency | Cycle | Progression | Status |
|---|---|---|---|---|
| Low research-peptide pattern | ~1–2 mg SC daily | Often several weeks | May increase | Community; unrelated to licensed Forzinity regimen |
| Common community pattern | ~5 mg SC daily | 8–12 weeks | Often fixed | Community/clinic |
| Broader historical community range | ~5–40 mg/day | Several weeks | Highly variable | Community; do not imply equivalence to approved product |
| Prime Life phased schedules | Low/standard/maximum schedules using changing dose and 3–7 dosing days/week | 8–12 weeks; 4–8 week washout claimed | Protocol-specific escalation/frequency changes | Clinic/community |
This entry changed materially in 2025: elamipretide is now an FDA-approved medicine (Forzinity) for Barth syndrome patients ≥30 kg. Research-vial 'SS-31' community schedules remain unapproved and should not borrow the product's efficacy/safety claims.
Evidence checked: 7 October 2026
Routes and formulations matter. A topical study does not validate injection; an IV research dose does not establish a fixed SC dose; and evidence for one molecular form must not be silently transferred to another.
Community reportsCommunity reports
What are people actually doing?
Community experience exists, but is anecdotal
Forums discuss schedules, effects and side effects, but posts are uncontrolled self-reports and product identity may be uncertain. Use them to understand what people report—not to estimate efficacy or establish a dose.
View the discussion on Reddit ↗
Safety and uncertaintySafety, side effects & what we don't know
Evidence is disease-specific, not proof of general “mitochondrial rejuvenation.”
Product identity, sterility and concentration are additional uncertainties for unlicensed research products. Evidence from an approved medicine or a clinical trial should not be transferred automatically to a differently sourced product.
QuestionsQuestions worth asking
What is the strongest evidence here?
SS-31/elamipretide now has a real US medicine story—but for a rare mitochondrial disease, not generic energy or anti-ageing.
Does a biological mechanism prove the claimed benefit?
No. Receptor activity, cell effects and animal results can justify research, but controlled human outcomes are a separate evidential step.
Is the research protocol a recommended dose?
No. The site reports study protocols to explain the evidence. It does not turn them into personalised self-use instructions.
Primary sourcesStudies, sources & further reading
External links are provided for transparency and further reading. Linking to a study, discussion or organisation does not mean Peptides Peptalk endorses every conclusion on that page.